EFOR · Everforth, Inc. · Stock research

Current Thesis

Everforth — formerly ASGN Incorporated, now trading as EFOR on the NYSE — sells IT and engineering services through two segments: Commercial ($701.7M of Q2 2026 revenue) and Federal Government ($305.3M). The narrative leg on offer is unchanged from the July framing: a headcount-based staffing and consulting base repricing as an AI, data and cloud delivery partner, with a federal AI kicker attached through the Everforth ECS brand. What has changed since early August is the shape of the move, not the facts underneath it. The 2026-07-30 session added 16.3% on the Q2 beat (adjusted EPS $0.91 versus $0.82 consensus; revenue $1,007.0M versus $990.9M consensus), and RSI(14) reached 94.5 at the 2026-08-07 close of $32.22. Fourteen sessions later, at the 2026-08-21 close of $32.70, RSI(14) reads 66.9 — the overbought condition unwound through time with price roughly flat. One new company headline landed inside that window: a four-year, $30M Defense Health Agency prime contract announced 2026-08-11 for predictive AI models, executive dashboards and cost/schedule/cyber-risk metrics across the DHA J-6 health IT portfolio.

The narrative is maturing. The dating is specific. Four discrete catalysts arrived between 2026-07-22 (Truist upgrade to Buy, target $33 to $36) and 2026-08-04 (AWS Premier Tier Services Partner expansion): the upgrade, the 2026-07-28 DEVCOM award, the 2026-07-29 print and 2026-07-30 session, and the AWS credential. Since then, one award release on 2026-08-11, carried mainly by government trade press (WashingtonExec, Futurum, citybiz) rather than mainstream financial media. The gains held without extending, and the calendar contains no company-dated event until the Q3 report in late October. Well known, still working, flow moderating.

Bullish and bearish views on Everforth, Inc.

The model's bull view on Everforth, Inc. (EFOR), in brief: Commercial trailing-twelve-month book-to-bill of 1.2 to 1, reported 2026-07-29 — bookings running ahead of revenue in the segment that is roughly 70% of the company, which is the mechanical precondition for the top line turning. The bear view: Both segments shrank year over year in Q2 2026: Commercial $701.7M versus $708.1M, Federal Government $305.3M versus $312.5M, for a consolidated 1.3% decline. Both cases follow in full.

Bull Case

• Commercial trailing-twelve-month book-to-bill of 1.2 to 1, reported 2026-07-29 — bookings running ahead of revenue in the segment that is roughly 70% of the company, which is the mechanical precondition for the top line turning.
• Two federal AI-flavoured prime awards inside fifteen days: the three-year, $115M DEVCOM Army Research Laboratory Nautilus program (2026-07-28) and the four-year, $30M DHA ITPSAS award (2026-08-11). The DHA scope is predictive-model and analytics delivery, not staff augmentation, which is the exact content the re-rating is being priced on.
• Margin guided flat to higher on flat revenue: Q2 2026 adjusted EBITDA of $96.7M at a 9.6% margin, against a Q3 guide of $95.0M–$105.0M, or 9.6%–10.3%.
• The Q3 adjusted EPS guide of $0.92–$1.10 brackets the $1.00 consensus with the midpoint above it; the Q2 adjusted EPS beat was 11% against consensus.
• Capital return continued through the drawdown: 0.4M shares repurchased for $11.5M in Q2 with approximately $923M of authorization remaining, and a $600M revolving facility closed in July 2026.
• Market capitalisation of roughly $1.34B (stockanalysis.com, 2026-08-22) sits against $1,007.0M of revenue recognised in Q2 alone.

Bear Case

• Both segments shrank year over year in Q2 2026: Commercial $701.7M versus $708.1M, Federal Government $305.3M versus $312.5M, for a consolidated 1.3% decline. The inflection lives in bookings commentary and has not reached reported revenue.
• Federal Government trailing-twelve-month new awards of $0.9B at a 0.8 to 1 book-to-bill as of 2026-07-29. The segment carrying the AI headlines is booking below what it burns, and the two new awards are multi-year ceilings — $115M over three years, $30M over four — against a segment that recognised $305.3M in a single quarter.
• Q3 revenue guidance of $994.0M–$1,024.0M puts the midpoint level with the $1,007.0M just delivered. No acceleration is in the guide.
• Consolidated gross margin of 28.3% in Q2 2026 was 40bp below Q2 2025.
• The adjusted-to-GAAP gap is wide and guided to persist: Q2 GAAP diluted EPS $0.35 against $0.91 adjusted; Q3 GAAP guide $0.36–$0.56 against an adjusted $0.92–$1.10.
• Sell-side marks sit under the market. Consensus target is $27.50 across seven analysts at a Hold consensus (stockanalysis.com, 2026-08-22), 15.9% below the 2026-08-21 close of $32.70. Wells Fargo cut to $26 on 2026-07-30; Baird's 2026-04-23 note cut its target from $62 to $38 and dates the derating.
• Total debt of $1,438.1M against $152.9M of cash at the Q2 report.

Setup & Price Structure

The 2026-08-21 close of $32.70 is 39.7% below the 52-week high of $54.25, with a three-month price change of +67.7%. Both numbers are true at once: a violent repair rally inside a structure that broke earlier in 2026.

The positioning evidence, stated as observables rather than as a verdict:

• RSI(14) fell from 94.5 on 2026-08-07 to 66.9 on 2026-08-21 while price moved from $32.22 to $32.70. The momentum extreme was worked off sideways; the gap from the 2026-07-30 session has not been retested.
• The stock trades above where the median covering analyst marks it — $27.50 consensus versus a $32.70 close. Among dated actions, only Truist's $36 (2026-07-22) sits above the last close; Wells Fargo's $26 (2026-07-30) and Baird's $38 (2026-04-23, a cut from $62) frame the range.
• Attention since 2026-08-11 has clustered in federal-contracting trade press rather than retail-facing financial media, and the release carried the Everforth ECS brand rather than the parent name.
• Share count moved down, not up: 0.4M shares repurchased for $11.5M in Q2 2026 with roughly $923M of authorization left. There is no equity issuance into this strength in the Q2 disclosure.
• The recent-filings record shows no insider transactions dated between the print and 2026-08-21. That is an absence in the feed reviewed, which is weaker evidence than a filed Form 4 either way.

The level that carries the thesis is the print-day advance itself. Roughly $28.50 is where the 2026-07-30 move is handed back and the sub-$28 sell-side anchors come back into the frame.

Catalyst Calendar (next 30 days)

• 2026-09-04 (est.) — U.S. Employment Situation report for August (BLS). Professional and business services payrolls are the highest-frequency proxy for Commercial demand, the ~70% of revenue carrying the 1.2-to-1 book-to-bill claim. This is the only dated event inside the 30-day window, and it is macro, not company-specific.
• 2026-09-30 — U.S. federal fiscal year end (just outside the window). Peak obligation period; Federal book-to-bill was 0.8 to 1 at the Q2 report.
• 2026-10-01 — Start of federal FY2027; appropriations or continuing-resolution decision. A lapse or extended CR delays new starts in a segment that was $305.3M of Q2 revenue.
• ~2026-10-21 (est.) — Q3 2026 results and Q4 guidance. Date unconfirmed by the company as of 2026-08-22. This is the first company-dated resolution point for the $994.0M–$1,024.0M revenue guide, the 9.6%–10.3% adjusted EBITDA margin guide, and whether bookings reach the reported top line.

What Would Change Our Mind

The structure that matters is the 2026-07-30 gap. The entire re-rating rests on that single session, and it has not yet been tested. A weekly close below $28.50 gives back the print-day advance and puts the $27.50 consensus mark and Wells Fargo's $26 into play; that is the gradeable break.

The narrative side breaks differently. Two months separate 2026-08-22 from the next company-dated event, and the 2026-08-11 award produced no measurable price extension. If the calendar runs to 2026-09-30 with no further contract releases and no upward estimate revisions, the label moves from maturing toward saturated on thin new bid, regardless of where price sits.

On the fundamentals, the read fails if Q3 revenue prints below the $994.0M guidance floor, or if Q4 guidance is set below the delivered Q3 number, or if Commercial trailing-twelve-month book-to-bill drops under 1.0 to 1 — that last one removes the only forward indicator currently pointing up.

The read strengthens on the opposite set: Federal book-to-bill crossing 1.0 to 1 at the October print, consolidated revenue turning positive year over year for the first time since the decline began, or gross margin printing above the 28.3% of Q2 2026 while adjusted EBITDA lands in the upper half of the $95.0M–$105.0M guide.

Correlation Notes

• The Commercial segment moves with staffing and professional-services cyclicals — Robert Half, Kforce, Insperity — and with the BLS professional-and-business-services payroll line. The 2026-09-04 report is the nearest high-frequency read on that exposure.
• The Federal segment tracks government-services names (Leidos, CACI, SAIC, Booz Allen Hamilton, Parsons) around appropriations headlines and the 2026-09-30 obligation window. That driver is independent of the commercial staffing cycle, so the two halves of the company can diverge inside a single quarter, as they did directionally in Q2 2026.
• The AI-delivery framing ties the name to Accenture, EPAM and Globant, where the open question is whether generative and agentic AI is additive bookings or substitution for billable hours in a headcount model. Accenture's fiscal fourth-quarter report, typically in the second half of September, is the largest single disclosure on that question and tends to move the whole IT-services complex.
• Leverage introduces rate sensitivity: $1,438.1M of total debt against $152.9M of cash at the Q2 2026 report, with a $600M revolver added in July 2026.
• Historical comparison work requires care. Price history, analyst notes and correlation studies dated before the rebrand run under ASGN Incorporated, and some data feeds still tag Everforth releases under the old ticker.